Company Filing History:
Years Active: 2024
Title: Howell Franklin Moffett: Innovator in Immunotherapy
Introduction
Howell Franklin Moffett is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative patents. With a total of 2 patents, Moffett's work focuses on enhancing the efficacy of chimeric antigen receptor (CAR) T cell therapies.
Latest Patents
Moffett's latest patents include groundbreaking advancements in CAR T cell technology. One of his patents, titled "ROR1 targeting chimeric antigen receptor," relates to polynucleotides encoding a chimeric polypeptide that includes a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. This innovation provides cells, such as T cells, that express CARs with improved properties, including reduced exhaustion due to the overexpression of c-Jun. Another significant patent is focused on "Recombinant cell surface markers," which involves EGFR-derived polypeptides containing short juxtamembrane sequences. This patent outlines methods to enhance the cell surface expression of truncated EGFR markers.
Career Highlights
Moffett is currently associated with Lyell Immunopharma, Inc., where he continues to push the boundaries of immunotherapy research. His work is instrumental in developing therapies that can potentially transform cancer treatment.
Collaborations
Moffett collaborates with esteemed colleagues, including Marc J. Lajoie and Scott Edward Boyken. Their combined expertise contributes to the advancement of innovative solutions in the field of immunotherapy.
Conclusion
Howell Franklin Moffett is a prominent figure in the realm of immunotherapy, with a focus on enhancing CAR T cell therapies through his innovative patents. His contributions are paving the way for future advancements in cancer treatment.